Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:45 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 4 Interventional

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

NCT01271218
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diet, Exercise
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Nov 1, 2026, 1:45 AM EST
Recruiting Phase 3 Interventional

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

NCT06150560
View directory record Official record
Conditions
Coarctation of Aorta, High Blood Pressure
Interventions
Losartan, Amlodipine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 1:45 AM EST
Active, not recruiting Not applicable Interventional

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

NCT01802346
View directory record Official record
Conditions
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
dietary intervention, nutritional support, laboratory biomarker analysis
Dietary Supplement · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional Results available

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

NCT00595413
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab
Drug · Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional Results available

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

NCT00637923
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin
Drug · Biological
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Nov 1, 2026, 1:45 AM EST
Recruiting Phase 2 Interventional

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05571059
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Ifetroban Sodium, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 1, 2026, 1:45 AM EST
Recruiting Phase 3 Interventional

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

NCT06650579
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix
Drug · Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 1, 2026, 1:45 AM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

Magnetic Resonance (MR) Spectroscopy and Diffusion Tensor Imaging in Determining Brain Injury and Subsequent Clinical Outcome in Patients of Moderate Brain Trauma

NCT00760903
View directory record Official record
Conditions
Brain Trauma
Interventions
Conventional MRI of the brain, MR spectroscopy (MRS), MR Diffusion Tensor Imaging (DTI)
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional

Treatment of Primary Menstrual Pain With Kanion Capsule

NCT00523146
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
Kanion Capsule
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sandy Springs, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00248495
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, pemetrexed disodium, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 3 Interventional

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064454
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535 Tablets (drug)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 1, 2026, 1:45 AM EST
Completed Not applicable Interventional

Using Patient Feedback to Improve Communication Regarding Glycemic Control to Patients With Diabetes

NCT01886170
View directory record Official record
Conditions
Diabetes
Interventions
Phase II of the Study: Information regarding Current Diabetes Control
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Nov 1, 2026, 1:45 AM EST
Completed Not applicable Interventional

Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors

NCT03319342
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Behavioral Intervention, Questionnaire Administration
Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Nov 1, 2026, 1:45 AM EST
Terminated Phase 2 Interventional Results available

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT01318642
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
Interventions
Gemcitabine, AMG 479, Placebo
Drug
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
San Francisco, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional Results available

RN624 In Adult Patients With Chronic Low Back Pain

NCT00584870
View directory record Official record
Conditions
Low Back Pain
Interventions
Naproxen, Placebo, PF-04383119 (RN624)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2Phase 3 Interventional Results available

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

NCT02055118
View directory record Official record
Conditions
Hunter Syndrome
Interventions
idursulfase-IT, No IT treatment
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Nov 1, 2026, 1:45 AM EST
Terminated Phase 2 Interventional Results available

Etoposide in Patients With COVID-19 Infection

NCT04356690
View directory record Official record
Conditions
COVID-19
Interventions
Etoposide
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 3 Interventional

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

NCT00002646
View directory record Official record
Conditions
Breast Cancer
Interventions
fenretinide, tamoxifen citrate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Nov 1, 2026, 1:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

National Prevalence and Impact of Noninvasive Prenatal Testing

NCT02284399
View directory record Official record
Conditions
Aneuploidy
Interventions
non-invasive prenatal testing
Other
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
4,488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • San Jose, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Nov 1, 2026, 1:45 AM EST
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Nov 1, 2026, 1:45 AM EST
Completed Phase 2 Interventional Results available

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
RN624, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Nov 1, 2026, 1:45 AM EST